PCM
CDLX icon

Pathway Capital Management’s Cardlytics CDLX Stock Holding History

Pathway Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,061
Closed -$667K – 5
2019
Q4 		$667K Buy
+1,061
New +$519K 0.34% 10

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Pathway Capital Management's CDLX Position: Q1 2020 in Review

Pathway Capital Management sold out of Cardlytics (CDLX) in Q1 2020, closing a stake of 1,061 shares — an estimated $667K sold.

Pathway Capital Management first reported a position in CDLX in Q4 2019 and held it in 1 quarter. The position peaked at $667K in Q4 2019. 142 funds tracked by Wall St. Rank hold CDLX as of Q1 2020.

  • Pathway Capital Management reported no remaining Cardlytics position as of Q1 2020 after selling out during the quarter.
  • Pathway Capital Management sold 1,061 Cardlytics shares in Q1 2020, an estimated $667K.
  • Pathway Capital Management first reported a position in Cardlytics in Q4 2019 and held it in 1 quarter.
  • Pathway Capital Management's Cardlytics position peaked at $667K in Q4 2019.
  • 142 funds tracked by Wall St. Rank held Cardlytics as of Q1 2020.

Based on Pathway Capital Management's 13F filing for Q1 2020, filed 4 May 2020.